Condition: Corneal Scar · Sponsor: Claris Biotherapeutics, Inc.
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.
This description comes directly from the study's public registry record.
Central Operations Representative · 949-354-1299 · clinicaltrials@clarisbio.com
Always discuss trial participation with your own doctor first.
| Loma Linda University Eye Institute | Loma Linda, California, United States | Recruiting |
| Midwest Cornea Associates, LLC | Carmel, Indiana, United States | Recruiting |
| Francis Price Jr, MD | Indianapolis, Indiana, United States | Recruiting |
| Minnesota Eye Consultants | Minnetonka, Minnesota, United States | Recruiting |
| Legacy Devers Eye Institute | Portland, Oregon, United States | Recruiting |
| Stuart A. Terry, MD PA | San Antonio, Texas, United States | Recruiting |
| Virginia Eye Consultants | Norfolk, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06257355